124 related articles for article (PubMed ID: 4060251)
1. Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer.
Crivellari D; Veronesi A; Magri MD; Tirelli U; Comoretto R; Barzan L; Caruso G; Carbone A; Grigoletto E
Tumori; 1985 Oct; 71(5):499-500. PubMed ID: 4060251
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer.
Grunberg SM; Felman IE; Gala KV; Johnson KB; Owens JC
Am J Clin Oncol; 1985 Oct; 8(5):393-5. PubMed ID: 4061373
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of VP-16-213 in advanced ovarian carcinoma.
Hillcoat BL; Campbell JJ; Pepperell R; Quinn MA; Bishop JF; Day A
Gynecol Oncol; 1985 Oct; 22(2):162-6. PubMed ID: 4054715
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of a new form of an oral administration of VP-16-213.
Lau ME; Hansen HH; Nissen NI; Pedersen H
Cancer Treat Rep; 1979 Mar; 63(3):485-7. PubMed ID: 371801
[TBL] [Abstract][Full Text] [Related]
5. [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
Kado M; Oshima S; Matsui Y; Shimokata K; Hara K; Kanda T; Shima K; Takenaka S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):116-21. PubMed ID: 3002282
[TBL] [Abstract][Full Text] [Related]
6. [Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer].
Cavalli F; Jungi WF; Brunner KW
Onkologie; 1981 Apr; 4(2):80-3. PubMed ID: 7022286
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study.
Bennett JM; Lymann GH; Cassileth PA; Glick JH; Oken MM
Am J Clin Oncol; 1984 Oct; 7(5):471-3. PubMed ID: 6594926
[TBL] [Abstract][Full Text] [Related]
8. [A phase II study of oral VP-16 in primary lung cancer].
Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of oral VP-16-213 in non-seminomatous testicular cancer.
Cavalli F; Klepp O; Renard J; Röhrt M; Alberto P
Eur J Cancer (1965); 1981 Feb; 17(2):245-9. PubMed ID: 7262161
[No Abstract] [Full Text] [Related]
10. [A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
Konno K; Nagahama F; Nakai Y; Nakabayashi T; Hiraga Y; Takebe K; Tamura M; Oizumi K; Sato M; Ito T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):931-7. PubMed ID: 3008671
[TBL] [Abstract][Full Text] [Related]
11. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
Suzuki K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial of VP-16-213 in ovarian cancer.
Maskens AP; Armand JP; Lacave AJ; De Jager RL; Hansen HH; Wolff JP
Cancer Treat Rep; 1981; 65(3-4):329-30. PubMed ID: 7016320
[No Abstract] [Full Text] [Related]
13. [A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma].
Nakada H; Ogawa M; Ingaki J; Horikoshi N; Inoue K; Usui N; Adachi K; Tada A; Yamazaki H; Mukaiyama T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1644-8. PubMed ID: 6476837
[TBL] [Abstract][Full Text] [Related]
14. Oral VP-16-213 in advanced bronchogenic carcinoma and toxic effects when combined with methotrexate.
Anderson G; Bowyer F; Williams L
Thorax; 1981 Jun; 36(6):462-4. PubMed ID: 7314017
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of etoposide for carcinoma of the prostate.
Walther PJ; Williams SD; Troner M; Greco FA; Birch R; Einhorn LH
Cancer Treat Rep; 1986 Jun; 70(6):771-2. PubMed ID: 3524825
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
Gynecol Oncol; 1978 Feb; 6(1):7-9. PubMed ID: 620951
[No Abstract] [Full Text] [Related]
18. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.
Anderson G; Payne H
Semin Oncol; 1985 Mar; 12(1 Suppl 2):21-2. PubMed ID: 3883504
[TBL] [Abstract][Full Text] [Related]
19. VP-16-213. A phase II trial using a weekly schedule.
Karp G; Antman K; Canellos G
Cancer Clin Trials; 1981; 4(4):465-7. PubMed ID: 7318129
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of etoposide in advanced prostate cancer.
Trump DL; Loprinzi CL
Cancer Treat Rep; 1984 Sep; 68(9):1195-6. PubMed ID: 6478456
[No Abstract] [Full Text] [Related]
[Next] [New Search]